JFG
VIR icon

JDM Financial Group’s Vir Biotechnology VIR Stock Holding History

JDM Financial Group’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-125
Closed -$2.91K – 221
2023
Q1 		$2.91K Hold
125
– – ﹤0.01% 205
2022
Q4 		$3.16K Buy
+125
New +$3.06K ﹤0.01% 199

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

JDM Financial Group's VIR Position: Q2 2023 in Review

JDM Financial Group sold out of Vir Biotechnology (VIR) in Q2 2023, closing a stake of 125 shares — an estimated $2.91K sold.

JDM Financial Group first reported a position in VIR in Q4 2022 and held it in 2 quarters. The position peaked at $3.16K in Q4 2022. 226 funds tracked by Wall St. Rank hold VIR as of Q2 2023.

  • JDM Financial Group reported no remaining Vir Biotechnology position as of Q2 2023 after selling out during the quarter.
  • JDM Financial Group sold 125 Vir Biotechnology shares in Q2 2023, an estimated $2.91K.
  • JDM Financial Group first reported a position in Vir Biotechnology in Q4 2022 and held it in 2 quarters.
  • JDM Financial Group's Vir Biotechnology position peaked at $3.16K in Q4 2022.
  • 226 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2023.

Based on JDM Financial Group's 13F filing for Q2 2023, filed 7 Aug 2023.